Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease

BACKGROUND Degranulation of eosinophils in target tissues is considered a key pathogenic event in major chronic eosinophilic diseases. However, because of a lack of appropriate methods, little is known about degranulation of eosinophils in common eosinophilic diseases. METHODS Using transmission electron microscopic (TEM) analysis, a novel approach has been devised and validated to quantify eosinophil degranulation in human tissues (assessed in individual cells as percentage granules with structural signs of protein release). Biopsy specimens from patients with inflammatory bowel disease, allergic rhinitis, asthma, and nasal polyposis were evaluated. RESULTS All conditions displayed a similar degree of local tissue eosinophilia, with no differences being observed in eosinophil numbers in the airway mucosa of patients with airway diseases and the colonic mucosa of those with inflammatory bowel disease (IBD). In contrast, marked differences in the mean (SE) extent of eosinophil degranulation were observed between the patient groups; IBD 9.3 (1.4)% altered granules, artificial and natural allergen challenge induced allergic rhinitis 67.8 (6.8)% and 86.6 (3.0)%, respectively, asthma 18.1 (2)%, and nasal polyposis 46.6 (7.6)%. CONCLUSIONS This study provides the first quantitative data which show that different eosinophilic conditions, despite having similar numbers of tissue eosinophils, may exhibit markedly different degranulation patterns. The present assessment of piecemeal degranulation would thus make it possible to delineate the conditions under which eosinophils are likely to contribute to disease processes. This novel type of analysis may also guide and validate anti-eosinophilic treatment options.

[1]  J. Erjefält,et al.  New aspects of degranulation and fates of airway mucosal eosinophils. , 2000, American journal of respiratory and critical care medicine.

[2]  J. Erjefält,et al.  Allergen-induced eosinophil cytolysis is a primary mechanism for granule protein release in human upper airways. , 1999, American journal of respiratory and critical care medicine.

[3]  M. Lindsay,et al.  Pharmacology of the eosinophil. , 1999, Pharmacological reviews.

[4]  J. Erjefält,et al.  Cytolysis and piecemeal degranulation as distinct modes of activation of airway mucosal eosinophils. , 1998, The Journal of allergy and clinical immunology.

[5]  J. Erjefält,et al.  Airway epithelial repair: breathtakingly quick and multipotentially pathogenic. , 1997, Thorax.

[6]  C. Persson Contennial notions of asthma as an eosinophilic, desquamative, exudative, and steroid-sensitive disease , 1997, The Lancet.

[7]  J. Erjefält,et al.  Eosinophil lysis and free granules: an in vivo paradigm for cell activation and drug development. , 1997, Trends in pharmacological sciences.

[8]  G. Gleich,et al.  Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. , 1997, The Journal of allergy and clinical immunology.

[9]  T. Halstensen,et al.  Monoclonal antibody EG2 does not provide reliable immunohistochemical discrimination between resting and activated eosinophils. , 1994, Journal of immunological methods.

[10]  K. Chung,et al.  Ultrastructural characterization of platelet-activating factor-stimulated human eosinophils from patients with asthma. , 1993, Clinical science.

[11]  H. Kita,et al.  Release of granule proteins from eosinophils cultured with IL-5. , 1992, Journal of immunology.

[12]  P. Jeffery,et al.  Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. , 1992, The American review of respiratory disease.

[13]  G. Gleich,et al.  The eosinophilic leukocyte and the pathology of fatal bronchial asthma: evidence for pathologic heterogeneity. , 1987, The Journal of allergy and clinical immunology.

[14]  P. Weller Human eosinophils. , 1997, The Journal of allergy and clinical immunology.